Most treatments for pain caused by knee osteoarthritis helped alleviate pain better than acetaminophen (Tylenol) – with one exception, according to a study published in the January 6 issue of the Annals of Internal Medicine
Most treatments for pain caused by knee osteoarthritis (OA) helped alleviate pain better than acetaminophen (Tylenol) – with 1 exception, according to a study published in the January 6 issue of the Annals of Internal Medicine.
Researchers, led by Raveendhara Bannuru, director of the Center for Treatment Comparison and Integrative Analysis at Tufts Medical Center and a research assistant professor of medicine, found that the exception was celecoxib, which is prescribed for joint pain.
Using data from 137 studies, the researchers compared the relative efficacy of 5 oral pain pills, including acetaminophen and ibuprofen, 2 injectable drugs, and oral and injectable placebos. They looked at randomized trials of adults with knee OA comparing 2 or more of the following: acetaminophen, diclofenac, ibuprofen, naproxen, celecoxib, intra-articular (IA) corticosteroids, IA hyaluronic acid, oral placebo, and IA placebo.
Related:How to develop drug formularies for pain treatment in women of reproductive age
“All treatments except acetaminophen showed clinically significant improvement from baseline pain,” Bannuru wrote. “For function, all interventions except IA corticosteroids were significantly superior to oral placebo. Intra-articular treatments were superior to nonsteroidal anti-inflammatory drugs, possibly because of the integrated IA placebo effect. Small but robust differences were observed between active treatments.”
Surprisingly, placebo injectables gave patients pain relief that was comparable to all of the oral pain medications tested. “We found injection placebos have more effect than oral placebos. We really want to explore that,” Bannuru told Medical Xpress. “As physicians, we can't separate the placebo effect from the treatment effect. As a patient, if I get that injection and my knee feels better, I don't really care whether it has active drug or placebo. So now we want to look into other placebos, like topical placebos and sham surgeries and sham acupuncture.”
Read next: When IV acetaminophen costs skyrocked, one health system did some new math
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More